婴幼儿“隐形杀手”：如何应对RSV感染？( 五 ) _健康小知识

2.BLOUNTREJr,MORRISJA,SAVAGERE.Recoveryofcytopathogenicagentfromchimpanzeeswithcoryza.ProcSocExpBiolMed.1956Jul;92(3):544-9.
3.CHANOCKR,ROIZMANB,MYERSR.Recoveryfrominfantswithrespiratoryillnessofavirusrelatedtochimpanzeecoryzaagent(CCA).I.Isolation,propertiesandcharacterization.AmJHyg.1957Nov;66(3):281-90.
4.儿童呼吸道合胞病毒感染诊断、治疗和预防专家共识[J].中华实用儿科临床杂志.2020(04):241-250.
5.BorchersAT,ChangC,GershwinME,GershwinLJ.Respiratorysyncytialvirus--acomprehensivereview.ClinRevAllergyImmunol.2013Dec;45(3):331-79.
6.CoultasJA,SmythR,OpenshawPJ.Respiratorysyncytialvirus(RSV):ascourgefrominfancytooldage.Thorax.2019Oct;74(10):986-993.
7.SarahGeogheganS,ErvitiA,CaballeroMT,etal.MortalityduetoRespiratorySyncytialVirus.BurdenandRiskFactors.AmJRespirCritCareMed.2017.195(1):96-103.
8.LuG,GonzalezR,GuoL,etal.Large-scaleseroprevalenceanalysisofhumanmetapneumovirusandhumanrespiratorysyncytialvirusinfectionsinBeijing,China.VirolJ.2011Feb10;8:62.
9.LiY,JohnsonEK,ShiT,etal.Nationalburdenestimatesofhospitalisationsforacutelowerrespiratoryinfectionsduetorespiratorysyncytialvirusinyoungchildrenin2019among58countries:amodellingstudy.LancetRespirMed.2021Feb;9(2):175-185.
10.https://www.hjf.org/case-studies/respigam-and-synagis
11.WuH,PfarrDS,LosonskyGA,KienerPA.ImmunoprophylaxisofRSVinfection:advancingfromRSV-IGIVtopalivizumabandmotavizumab.CurrTopMicrobiolImmunol.2008;317:103-23.
12.Births:Finaldatafor2020.NationalVitalStatisticsReports;vol70no17.Hyattsville,MD:NationalCenterforHealthStatistics.2022.
13.HallCB,WeinbergGA,BlumkinAK,etal.Respiratorysyncytialvirus-associatedhospitalizationsamongchildrenlessthan24monthsofage.Pediatrics.2013Aug;132(2):e341-8.
14.RainischG,AdhikariB,MeltzerMI,LangleyG.Estimatingtheimpactofmultipleimmunizationproductsonmedically-attendedrespiratorysyncytialvirus(RSV)infectionsininfants.Vaccine.2020Jan10;38(2):251-257.
15.WuP,HartertTV.Evidenceforacausalrelationshipbetweenrespiratorysyncytialvirusinfectionandasthma.ExpertRevAntiInfectTher.2011.Sep;9(9):731–745.
16.TianD,BattlesMB,MoinSM,etal.Structuralbasisofrespiratorysyncytialvirussubtype-dependentneutralizationbyanantibodytargetingthefusionglycoprotein.NatCommun.2017Nov30;8(1):1877.
17.ZhuQ,McLellanJS,KallewaardNL,etal.Ahighlypotentextendedhalf-lifeantibodyasapotentialRSVvaccinesurrogateforallinfants.SciTranslMed.2017May3;9(388):eaaj1928.
18.GriffinMP,YuanY,TakasT,etal.Single-DoseNirsevimabforPreventionofRSVinPretermInfants.NEnglJMed.2020Jul30;383(5):415-425.
19.HammittLL,DaganR,YuanY,etal.NirsevimabforPreventionofRSVinHealthyLate-PretermandTermInfants.NEnglJMed.2022Mar3;386(9):837-846.
20.ArnoldC.11clinicaltrialsthatwillshapemedicinein2022.NatMed.2021.27,2062–2064
21.https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-says-key-trial-data-shows-its-rsv-vaccine-is-truly-exceptional-2022-10-13/
22.VenkatesanP.Nirsevimab:apromisingtherapyforRSV.LancetMicrobe.2022May;3(5):e335.
23.https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-22-23/03-RSV-McMorrow-508.pdf返回搜狐，查看更多
责任编辑：